Sonja Chiappetta1, Christine Stier2, Simone Squillante2, Sophia Theodoridou2, Rudolf A Weiner2. 1. Department of Obesity and Metabolic Surgery, Sana Klinikum Offenbach, Offenbach am Main, Germany. Electronic address: sonja1002@gmx.de. 2. Department of Obesity and Metabolic Surgery, Sana Klinikum Offenbach, Offenbach am Main, Germany.
Abstract
BACKGROUND: The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. OBJECTIVES: The aim of this study was to determine whether the EOSS can also be used in predicting postoperative outcome and 30-day mortality after metabolic surgery. SETTING: Center of maximum care in Germany METHODS: We collected data prospectively for patients undergoing laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), or laparoscopic omega-loop gastric bypass (LOLGB). The data collected included preoperative EOSS score, gender, age, BMI, waist circumference, waist-to-hip ratio, co-morbidities, early postoperative complications, and 30-day mortality. RESULTS: A total of 534 patients were included. The mean BMI was 45.57 kg/m2 (range 35-64.5) for LRYGB patients (n = 168), 53.27 kg/m2 (range 35.1-82.1) for LSG patients (n = 282), and 49.42 kg/m2 (range 36-73.1) for LOLGB patients (n = 84). The total postoperative complication rate was 8.99%. The most common EOSS stage was 2 (70.6% of patients), followed by stages 3 (12.55%), 1 (11.61%), and 0 (5.06%). The postoperative complication rates after LRYGB, LSG, and LOLGB were 0% for EOSS 0 and 1.61% for EOSS 1. The postoperative complication rates were 8.22% for EOSS 2 and 22.39% for EOSS 3. CONCLUSION: Patients with EOSS≥3 have a higher risk of postoperative complications. Our data confirm that the EOSS is useful as a scoring system for the selection of obese patients before surgery and suggest that it may also be useful for presurgical stratification and risk assessment in clinical practice. Patients should be recommended for obesity surgery when their EOSS stage is 2 to prevent impairments associated with metabolic disease and to reduce the risk of postoperative complications.
BACKGROUND: The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obesepatients for obesity surgery has been suggested. OBJECTIVES: The aim of this study was to determine whether the EOSS can also be used in predicting postoperative outcome and 30-day mortality after metabolic surgery. SETTING: Center of maximum care in Germany METHODS: We collected data prospectively for patients undergoing laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), or laparoscopic omega-loop gastric bypass (LOLGB). The data collected included preoperative EOSS score, gender, age, BMI, waist circumference, waist-to-hip ratio, co-morbidities, early postoperative complications, and 30-day mortality. RESULTS: A total of 534 patients were included. The mean BMI was 45.57 kg/m2 (range 35-64.5) for LRYGB patients (n = 168), 53.27 kg/m2 (range 35.1-82.1) for LSG patients (n = 282), and 49.42 kg/m2 (range 36-73.1) for LOLGB patients (n = 84). The total postoperative complication rate was 8.99%. The most common EOSS stage was 2 (70.6% of patients), followed by stages 3 (12.55%), 1 (11.61%), and 0 (5.06%). The postoperative complication rates after LRYGB, LSG, and LOLGB were 0% for EOSS 0 and 1.61% for EOSS 1. The postoperative complication rates were 8.22% for EOSS 2 and 22.39% for EOSS 3. CONCLUSION:Patients with EOSS≥3 have a higher risk of postoperative complications. Our data confirm that the EOSS is useful as a scoring system for the selection of obesepatients before surgery and suggest that it may also be useful for presurgical stratification and risk assessment in clinical practice. Patients should be recommended for obesity surgery when their EOSS stage is 2 to prevent impairments associated with metabolic disease and to reduce the risk of postoperative complications.
Authors: M G Grammatikopoulou; M Chourdakis; K Gkiouras; P Roumeli; D Poulimeneas; E Apostolidou; I Chountalas; I Tirodimos; O Filippou; S Papadakou-Lagogianni; T Dardavessis Journal: J Endocrinol Invest Date: 2018-01-08 Impact factor: 4.256